Rhizopus stolonifer as a biocatalyst for cyclic dipeptide production and artemisinin/artemether biotransformation
Applied Microbiology and Biotechnology · 05.11.2026
DOI: 10.1007/s00253-026-14082-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 05.11.2026. Verfasst von Ji-Chen Zhang und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Fungi are prolific producers of chemically diverse natural products and biocatalytically active enzymes, yet the biosynthetic and biotransformation potential of many fungal species remains underexplored. This study establishes Rhizopus stolonifer as a promising platform for both natural-product discovery and selective biotransformation of bioactive molecules. Ten cyclic dipeptides (CDPs) and over seventy additional metabolites were tentatively identified using an integrated metabolomics approach combining gas chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry, and one- and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. Three major CDPs, cyclo(L-Leu-L-Pro), cyclo(L-Ile-L-Pro), and cyclo(L-Phe-L-Pro), were subsequently isolated and characterized, with their stereochemical configurations established. In parallel, R. stolonifer was utilized as a microbial platform for the biotransformation of antimalarial drugs artemisinin and artemether. The resulting derivatives were generated through deoxygenation, site-selective hydroxylation, and structural rearrangement. Time-course NMR analyses provided evidence for the proposed biotransformation pathways. Genome mining revealed six putative non-ribosomal peptide synthetase biosynthetic gene clusters and thirteen cytochrome P450 monooxygenases, suggesting a genetic basis for CDP biosynthesis and artemisinin biotransformation, respectively. These results underscore the dual utility of R. stolonifer as a rich source of CDPs and a versatile biocatalyst for the transformation of artemisinin derivatives. Key points Rhizopus stolonifer is a rich source of cyclic dipeptides (CDPs). R. stolonifer biotransforms artemisinin and artemether into multiple derivatives. Non-ribosomal peptide synthetase pathways may underpin CDP production.
Förderung
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Zhang, J., Fadayomi, I., Shi, Y., Yang, K., Qazi, A., Khan, S., Ren, X., & Li, W. (2026). Rhizopus stolonifer as a biocatalyst for cyclic dipeptide production and artemisinin/artemether biotransformation. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14082-8
Vancouver
Zhang J, Fadayomi I, Shi Y, Yang K, Qazi A, Khan S, et al. Rhizopus stolonifer as a biocatalyst for cyclic dipeptide production and artemisinin/artemether biotransformation. Applied Microbiology and Biotechnology. 2026. doi:10.1007/s00253-026-14082-8
BibTeX
@article{Zhang2026,
author = {Zhang, Ji-Chen and Fadayomi, Idowu and Shi, Yong-Qiang and Yang, Ke-Xin and Qazi, Areesha and Khan, Sofia and Ren, Xiao-Dong and Li, Wen-Wu},
title = {Rhizopus stolonifer as a biocatalyst for cyclic dipeptide production and artemisinin/artemether biotransformation},
journal = {Applied Microbiology and Biotechnology},
year = {2026},
doi = {10.1007/s00253-026-14082-8}
}
EUVIMED